• Aucun résultat trouvé

Modified Gemcitabine-loaded lipid nanocapsules: when a drug participates to the structure of a nanomedicine

N/A
N/A
Protected

Academic year: 2022

Partager "Modified Gemcitabine-loaded lipid nanocapsules: when a drug participates to the structure of a nanomedicine"

Copied!
1
0
0

Texte intégral

(1)

! " # $ % &'(( # $ )* + ,--.. / - 0

+ ! 1 2 + 3

3 + ! 4 &56 7 8 8 8 4 6 7 9 9 +9 8 33

!

"

3 + ! 4 &56 7 8 8 8 4 6 7 9 9 +9 8 33

9 + 7 8 3 8 + + + &5 7 : 9 3

3 9 + ! 3 &5 /8 7 3 ) ! 9 3

! 7 8 # 89 &5 8 / 2

7 9 + 2 9 +9 9 9 2 +

# $ % & ' & !()' * ;9

3 9 9 + 8 7 46 8 9 + 3 4 6

8 2 8 89 9 + 8 8 8 4 6 9 3

3 426 / 33

" & +,!'

- -

!

.!

# -

- /0 - #

# ! ! 9 8 8 8 < 89 "

89 3 ;9 3 3 8 8 39 +

+ + 9 3 37 9 +9 8

7 7 8 # 9 9 + 2 ! 9 7

! 3 9 7 9 7 ;9 " 9 + 7 8 3 !

9 ! 9 #= 9 3 3 !

8

1 2

!

! , 4 6 + ! >&) % &. % $8 3 , 4 6 + !

3

) +9 8 3 " 9 + 89

7 3 7 9 33 -'

!

;9 2 8 8 3 33 3 7 + 2 9 7 9 3/ 9 3 " 1 !() # ! 4 $

* ;9 8 3 ! ! 9 3 9 3 ! 3 9 + ;9 3 9 ?@ &5 9 7 5

) +9 8 3 " 9 + 89

4) 6 7 8 3 9

8

(++6 3 &5

8 9 + 2 9

4 A 9 6

0 + 5< 8 9 + 3+ ! &5

/9 ! + 3 ! 5 B?

# ! (6 !() # ! )786 !() # ! 86 !() # ! (+6

!()

8 4@6 &'' &'' &'' &''

,'

?' (' B' A' -'

' &'' 5'' .''

*&'

3

# !) 2 9

# !) (6 !()

# !) )786 !()

# !) 86 !()

# !) (+6 !()

7 3 7 9 33

3 &5 ;9 7

3 : ! ! 89

8 8 : 8

+ 2 = : C

# ! 4

* $ / * 7

1 # ! !()

7 &< 8 8

" 4 6 + 4! < 5

?@ &56

&

&'

&''

&'''

# ! 86

!()

# ! 86

!() :

# ! 86

!() : !

# ! 86

!() :

# ! 86

;;;&'

D DD EE

EE

* ;9 8 3 ! &5! 9 3 9 3 ! &53 9 + ;9 3 9 ?@ &5 9 7 5

!();9 3 9 7 9 89 !

n= 3 ; mean±SD ANOVA 1F post hocScheffé

&5 )$

$ 3

; +

'

?

&'

&?

5' 5?

.' .?

,'

' & 5 . , ? ( B

&.'

!() & . '

!

&'

&''

&'''

&''''

;;;&' EE

E

E

&'

&''

&'''

&''''

;;;&'

D DD EE

E

* p < 0.05

** p < 0.01

;9 2 8 8 3 33 3 3 7 9 + 7 9 33 : 3 7 +

2 9 7 9 3/ 9 3 " 4 F.G ±$> H I &0 $ 9 33 < 8 J ' '?<< 8 J

' '&6# ! !() = * 7

> 8 7 : 9 : 9 : 3+ !

9 4 F.G ±$> 6 > 8 9 7 3 3

+ K 7 3 7 9 9 8 89 8 + 7 4

!() # ! $ 5

7

/ 2 3 3 &5 2 + !

9 9 4 : C6 7 33

4),(' ?,-< 7 9 + G 5

/ .< 7 9 8 6 ;9 8 7

! ;$ 3 ,A 9 3 ! 4 F.G ±

$> 6 / * >7 !()

5 %?+ $ 18%@$ 5'

,' (' A'

&''

!4&6'

%?+

5' ,' (' A'

&''

!4&6'

25 A

&5 :

&5

&

# ! 86

!()

# ! 86

!() (B

# ! 86

!() )(

# ! C$86

!()

# ! C$86

!() (B

# ! C$86

!() )(

&

# ! 86

!()

# ! 86

!() (B

# ! 86

!() )(

# ! C$86

!()

# ! C$86

!() (B

# ! C$86

!() )(

# ! (+6

!()

# ! (+6

!() (B

# ! (+6

!() )(

5' ,' (' A'

&''

!4&6'

18%@

5' ,' (' A'

&''

!4&6'

! )

8+ )8

5 %?+ $ 18%@$

! ) 25 A 7 '

5'

' & ? &' 5? ?' B? &''

!4&6'

! &D '

'

' & ? &' 5? ?' B? &''

!4&6'

! &D '

&5

8 3 8 89 + ! 8 9 9 +9 2 3 33 ! 2 9 7 9 + 8 8

! 33 + 8 3 2 2

E # ! ! #I + 7 9 7 9 + + 3 9 3

# ! ! 7 9 9 3 ! + + ! 2 8 !

9 2 3

' 5'

' & ? &' 5? ?' B? &''

!4&6'

! &D '

' 5'

' ?' &'' &5? &?' &B? 5'' 5?'

!4&6'

! &D '

Références

Documents relatifs

Feasibility with a 55 nm Z-Ave loaded LNC gel with 10% drug concentration (Gem-C12/Labrafac w/w) was not performed due to the instantaneous gelation process directly aer the

The different in vitro and in vivo experiments performed with this ferrocifen-loaded nanocarrier have revealed promising results in several multidrug-resistant cancer cell lines such

Despite the increase in tumor perfusion and the decreases in tumor vessel area and the number of Ki67 þ cells achieved with SFN-LNCs, these effects were not sufficient to modify

Giovanna Lollo 1,2,3 , Martina Bocchiardo 2,3 , Kevin Matha 2,3 , Marion Pitorre 2,3 , Guillaume Bastiat 2,3 , Jerome Bejaud 2,3 , Maria Stella Sasso 4

V Anaïs Vaissiière CNRS - Centre de Biologie cellulaire de Montpellier Montpellier, France Lucie Valero Université Paris Descartes - UTCBS Paris, France Mathieu Varache CEA

In the EG7-OVA mouse tumor model, very low dose GemC12-LNCs (molar equivalent of 11 mg/kg GemHCl) strongly decreased the frequency of M-MDSCs in the spleen and tumor, while other

For biodistribution experiments, mice were sacrificed at sequential time points from DiD-LNC injection (24h, 48h, 72h) and organs (i.e. kidneys, liver, spleen, lung, heart,

Pharmacokinetic disposition of IVM in different animal species may be affected by formulation design since the vehi- cle in which these compounds are formulated may influence